{"filing":{"accession_number":"0001628280-26-037377","cik":"0002023658","ticker":"BCAX","company_name":"Bicara Therapeutics Inc.","form":"8-K","filing_date":"2026-05-21","report_date":null,"primary_document":"bcax-20260521.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/2023658/000162828026037377/bcax-20260521.htm"},"events":[{"id":9580,"run_id":8403,"accession_number":"0001628280-26-037377","anchor_item_number":"8.01","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.75,"summary":"The filing discloses a press release announcing clinical trial results for Bicara's lead candidate ficerafusp alfa plus pembrolizumab, demonstrating three-year overall survival and deep responses in HPV-negative HNSCC. While this is a clinical data announcement rather than financial earnings, it represents material clinical progress that would significantly affect investor assessment of the company's pipeline and commercial prospects. The press release is attached as Exhibit 99.1 and incorporated by reference, consistent with how material clinical milestones are disclosed under Item 8.01.","company_name":"Bicara Therapeutics Inc.","ticker":"BCAX","filing_date":"2026-05-21","form":"8-K","submitted_at":null,"items":[{"id":1244,"accession_number":"0001628280-26-037377","item_number":"8.01","item_title":"Other Events.","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.75,"reasoning":"The filing discloses a press release announcing clinical trial results for Bicara's lead candidate ficerafusp alfa plus pembrolizumab, demonstrating three-year overall survival and deep responses in HPV-negative HNSCC. While this is a clinical data announcement rather than financial earnings, it represents material clinical progress that would significantly affect investor assessment of the company's pipeline and commercial prospects. The press release is attached as Exhibit 99.1 and incorporated by reference, consistent with how material clinical milestones are disclosed under Item 8.01.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-05-22T03:05:36.124697+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":1244,"accession_number":"0001628280-26-037377","item_number":"8.01","item_title":"Other Events.","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.75,"reasoning":"The filing discloses a press release announcing clinical trial results for Bicara's lead candidate ficerafusp alfa plus pembrolizumab, demonstrating three-year overall survival and deep responses in HPV-negative HNSCC. While this is a clinical data announcement rather than financial earnings, it represents material clinical progress that would significantly affect investor assessment of the company's pipeline and commercial prospects. The press release is attached as Exhibit 99.1 and incorporated by reference, consistent with how material clinical milestones are disclosed under Item 8.01.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-05-22T03:05:36.124697+00:00","company_name":"Bicara Therapeutics Inc.","ticker":"BCAX","filing_date":"2026-05-21"}]}